ZYLOX-TONBRDG.MED.TECH.H1 Total Liabilities
ZYLOX-TONBRDG.MED.TECH.H1 total liabilities. Based on the latest financial reports, ZYLOX-TONBRDG.MED.TECH.H1 (818) has total liabilities worth €341.97 Million EUR (≈ $399.80 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of ZYLOX-TONBRDG.MED.TECH.H1 to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
Total liabilities of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024. This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's total liabilities have evolved over time, based on quarterly financial data.
ZYLOX-TONBRDG.MED.TECH.H1 Competitors by Total Liabilities
The table below lists competitors of ZYLOX-TONBRDG.MED.TECH.H1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FastPartner AB (publ)
ST:FPAR-A
|
Sweden | Skr21.73 Billion |
|
Baotailong New Materials Co Ltd
SHG:601011
|
China | CN¥5.48 Billion |
|
Hiconics Drive Tech Co
SHE:300048
|
China | CN¥3.90 Billion |
|
Advanced Wireless Semiconductor Co
TWO:8086
|
Taiwan | NT$2.31 Billion |
|
Sinodata Co Ltd
SHE:002657
|
China | CN¥665.87 Million |
|
Ricegrowers Ltd
AU:SGLLV
|
Australia | AU$646.47 Million |
|
Credit Corp Group Ltd
AU:CCP
|
Australia | AU$507.87 Million |
|
Phreesia Inc
NYSE:PHR
|
USA | $103.14 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down ZYLOX-TONBRDG.MED.TECH.H1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 818 total assets.
Liquidity & Leverage Metrics
ZYLOX-TONBRDG.MED.TECH.H1 Total Liabilities Ratios Explained
ZYLOX-TONBRDG.MED.TECH.H1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZYLOX-TONBRDG.MED.TECH.H1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual total liabilities of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €351.56 Million ≈ $411.01 Million |
+7.08% |
| 2023-12-31 | €328.32 Million ≈ $383.84 Million |
+105.79% |
| 2022-12-31 | €159.54 Million ≈ $186.52 Million |
+53.98% |
| 2021-12-31 | €103.61 Million ≈ $121.13 Million |
-- |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracrania… Read more